4'''',5,7-三羟基二氢黄酮与人血清白蛋白相互作用的光谱学研究

应用紫外吸收光谱、荧光光谱和红外光谱等方法对人血清白蛋白(HSA)与4',5,7-三羟基二氢黄酮(naringenin,NAR)相互作用的机理进行了研究.紫外光谱显示,在生理pH下NAR分子中A环7位的酚羟基发生部分解离,7位酚羟基的解离使A环与B环上羰基形成的共轭体系的紫外吸收峰发生明显红移;药物与蛋白质的相互作用使该谱带发生了进一步的红移,说明该共轭体系参与了与蛋白质的相互作用.在药物与蛋白质浓度比(cNAR/cHSA)为0.1～10的范围内,NAR在HSA上只有一个结合位点(可能位于site I),结合常数为1.27×105L·mol~(-1)(n=5,RSD小于5%).研究了不同pH值条件下药物对蛋白质荧光猝灭的影响,发现药物分子中的没有解离的活性基团在结合过程中发挥着主导作用.在缓冲水溶液和重水溶液中分别测定了与药物作用前后蛋白质二级结构的变化.随着药物浓度的增加,NAR和HSA之间的相互作用使HSA的α-螺旋结构的含量明显降低,而β-折叠和β-转角结构的含量增加,无轨结构在药物浓度较高时也有少量的增加.结合紫外吸收光谱、荧光光谱和红外光谱结果,探讨了HSA与NAR相互作用的模式.     

稀土金属离子与人血清白蛋白的相互作用

本文用荧光光谱、紫外-可见吸收光谱法和循环伏安法研究了稀土金属离子Eu(Ⅲ)、Pr(Ⅲ)与人血清白蛋白(HSA)的相互作用。实验发现：Eu(Ⅲ)和Pr(Ⅲ)对HSA有较强的荧光猝灭作用。用Stern-Volmer方程分别对实验数据进行处理，结果发现：HSA与Eu(Ⅲ)、Pr(Ⅲ)发生反应生成了新的复合物，发生了分子内的非辐射能量转移。Eu(Ⅲ)、Pr(Ⅲ)对HAS的荧光猝灭作用，属于静态荧光猝灭。荧光猝灭图表明：Eu³⁺和Pr³⁺在HSA分子中至少有两类结合位点，Eu³⁺与HSA形成2.76∶1的复合物，结合常数lgK分别为12.03和9.05；Pr³⁺与HSA形成2.2∶1的复合物，结合常数lgK分别为9.89和6.97。同时用圆二色谱及同步荧光光谱法探讨了 Eu(Ⅲ)和Pr(Ⅲ)对HSA构象的影响。     

罗布麻活性成分与人血清白蛋白结合的光谱学研究

应用荧光和紫外光谱研究了人血清白蛋白与罗布麻活性成分槲皮素(QUE)、芸香苷(RUT)和儿茶素(CAT)的结合机理. 在QUE与蛋白质浓度比小于3.5时, 其荧光猝灭机理主要是静态猝灭, 在药物浓度较高时动态猝灭所占的比例增加; RUT在整个实验浓度范围内对蛋白质的荧光猝灭机理为静态猝灭; CAT与蛋白质之间不能形成复合物, 其荧光猝灭主要由动态猝灭产生. QUE和RUT分别与蛋白质形成1∶1的复合物, 结合常数分别为(1.51±0.13)×10⁵和(0.81±0.08)×10⁵ L•mol^－1. 由于激发态质子转移, 与蛋白质的相互作用引起QUE和RUT内源荧光发射峰强度的明显增加, 进一步证实了它们与蛋白质的结合. 与蛋白质的结合也引起了QUE紫外吸收带的明显红移, 说明药物分子中的酚羟基发生了解离, 以离子形式与蛋白质发生作用. RUT的紫外吸收谱带没有明显移动, 说明它主要以中性状态与蛋白质结合. 应用与蛋白质作用后药物分子紫外吸收光谱的二阶导数谱, 对药物与蛋白质的结合模式进行了深入探讨.     

3-溴丙酮酸与人血清白蛋白相互作用的光谱学研究

运用荧光光谱、紫外可见吸收光谱和圆二色光谱法研究了抗肿瘤药物3-溴丙酮酸(3-Bromopyruvic acid,3-BrPA)与人血清白蛋白(Human serum albumin,HSA)的相互作用.3-BrPA对HSA的猝灭机制属于静态猝灭,并发生分子间非辐射能量转移.热力学数据显示,二者之间的作用力主要为静电作用;同步荧光光谱表明,3-BrPA与蛋白质中接近色氨酸残基的区域发生了相互作用;荧光光谱研究发现,Zn2+存在时3-BrPA对HSA的猝灭程度进一步增强;圆二色光谱法研究蛋白二级结构结果显示,3-BrPA对HSA的结构影响非常小.     

荧光法研究偏钒酸钠与牛血清白蛋白的相互作用

本文用荧光光谱和紫外可见吸收光谱研究了在模拟人体生理条件下，偏钒酸钠与牛血清白蛋白(BSA)结合反应的特征，研究了紫外灯(253.7 nm)照射对偏钒酸钠与BSA结合的影响。紫外吸收光谱显示，加入偏钒酸钠后，牛血清白蛋白的紫外吸收降低，表明偏钒酸钠与BSA形成了缔合物。荧光猝灭光谱显示偏钒酸钠对牛血清白蛋白有较强的荧光猝灭作用，荧光猝灭机理符合静态机制。缔合物的稳定常数分别为：K_s=0.357×10⁴(25 ℃)，K_{s相似文献}   

瓜环与2,2'-联吡啶衍生物的相互作用

利用¹H NMR技术、紫外吸收光谱及荧光光谱方法, 考察了对六、七以及八元瓜环与多种2,2'-联吡啶衍生物相互作用形成的主客体配合物结构及光谱性质. 研究结果显示, 不同的2,2'-联吡啶衍生物与瓜环作用不仅形成多种不同包结比的稳定包结配合物, 且所形成的主客体包结配合物的结构及光谱性质也各不相同; 同时用几种方法协同考察起到了互为补充、互为验证的良好效果.     

烟碱与人血清蛋白相互作用的光谱研究

在0.1 mol/L的磷酸氢二钠-柠檬酸体系中,采用荧光光谱、紫外吸收光谱研究了人血清蛋白与烟碱的相互作用.荧光滴定表明这种相互作用使HSA的内源荧光猝灭.通过猝灭常数、结合常数和结合位点数的计算,证明了这种猝灭为静态猝灭机制.尼古丁和HSA形成11稳定复合物;考察不同温度和酸度下的猝灭作用,进一步证实其静态猝灭行为和疏水作用机制.紫外吸收光谱和同步荧光光谱表明,相互作用引起HSA构象变化,而同步荧光光谱提示结合位点更接近于色氨酸.     

紫外光谱、荧光光谱及平衡透析研究磷钨杂多酸与HSA或BSA的结合平衡

采用紫外光谱法、荧光光谱法并结合平衡透析法研究了磷钨杂多酸(H₇[P(W₂O₇)₆]·xH₂O)与人血清白蛋白(human serum albumin, HSA)或牛血清白蛋白(bovine serum albumin, BSA)的结合平衡. 观测到在生理pH 7.43条件下磷钨杂多酸使HSA和BSA的紫外吸收峰增强, 并使HSA和BSA的特征荧光峰猝灭. Scatchard图分析表明, 磷钨酸在HSA和BSA中均有一个强结合部位. 通过非线性最小二乘法拟合Bjerrum方程, 得出磷钨酸-HSA和磷钨酸-BSA体系的逐级稳定常数.     

双核钒席夫碱配合物[VO(μ2-O)(o-Vanillin-en)]2的合成、结构及与DNA相互作用

在甲醇体系中乙酰丙酮氧钒与邻香草醛缩牛磺酸钾席夫碱在乙二胺存在下反应得到一个双核钒配合物。通过红外光谱和X-射线单晶衍射对其进行了表征。晶体结构表明该化合物的晶体属于三斜晶系，P1空间群，晶胞参数为a=0.898 67(19)nm，b=1.159 3(3) nm，c=1.200 0(3) nm，α=106.872(3)°，β=102.718(4)°，γ=94.905(3)°，Z=2。通过紫外吸收光谱法和循环伏安法研究了钒配合物与小牛胸腺DNA间的相互作用。紫外吸收光谱法得到配合物与DNA的结合常数为1.77×10⁴ dm³·mol^-1。     

2-甲基-2,5′-(乙烯基)-二-8-羟基喹啉锌配合物的合成与荧光特性

设计合成了8-羟基喹啉衍生物3和4以及它们的金属锌配合物5和6,化合物3和4经质谱(MS)、元素分析(EA)、红外光谱(IR)、紫外光谱(UV)、核磁共振氢谱( ¹H NMR)进行表征,并测定了它们的荧光性质,与2-甲基-8-羟基喹啉(λ_max=390 nm)比较表明,化合物3和4的荧光红移80～150 nm;用X射线单晶衍射仪测定了化合物3的晶体结构,晶体属于三斜晶系,空间群P1,a=0.706 87(5) nm,b=0.962 03(6) nm,c=1.221 09(8) nm,α=86.735(4)°,β=87.840(4)°,γ=74.333(4)°,V=0.798 01(9) nm³,Z=2,D_c=1.367 Mg·m^-3,μ=0.089 mm^-1,F(000)=344,wR₁=0.055 2,wR₂=0.158 1。化合物3的晶体结构确认了2-甲基-8-羟基喹啉甲酰化是在5位。测定了化合物5和6的荧光光谱及其荧光寿命,结果表明,化合物5和6发光的峰值为620 nm 和623nm,能够发出橙色的荧光,与2-甲基-8-羟基喹啉锌(λ_max=515 nm)比较,发生了明显的红移。化合物5和6的寿命分别为1.57 ns和1.77 ns,呈单指数衰减。     

Spectroscopic Investigation on the Binding of the Antitumoral Pd(II) Complex to Human Serum Albumin

The interaction of human serum albumin (HSA) with 1,10‐phenanthroline‐ethyldithiocarbamatopalladium(II) nitrate complex, [Pd(phen)(Et‐dtc)]NO₃, has been studied by using absorption, fluorescence and circular dichroism spectroscopic measurements. UV‐Vis studies imply that The peptide strands of protein molecules extended more (denatured) upon the addition of Pd(II) complex. This process is spontaneous and exothermic. A fluorescence quenching reaction of Pd(II) complex and HSA was observed and quenching mechanism was suggested as static quenching according to Stern‐Volmer equation. The number of binding sites (n) and apparent association constant (K_A) were calculated using fluorescence quenching data. The circular dichroism results revealed the conformational changes in secondary structure of protein upon its interaction with Pd(II) complex. In these interaction studies, several thermodynamic and binding parameters are also determined which may provide deeper insights into structural changes induced by an antitumor Pd(II) complex on the protein as the metal complex side effects.     

Insight into the binding evaluation of two antitumor Pd(II) complexes with human serum albumin

The interaction between two novel water-soluble palladium(II) complexes (Pd(bpy)(pyr-dtc)]NO₃, complex I and ([Pd(phen)(pyr-dtc)]NO₃, complex II, where bpy = 2,2′-bipyridine, phen = 1,10-phenanthroline and pyr-dtc = pyrrolidinedithiocarbame) and human serum albumin (HSA) was investigated by fluorescence quenching spectroscopy, synchronous, fluorescence resonance energy transfer (FRET) and three-dimensional fluorescence combined with UV–Vis absorption spectroscopy and circular dichroism technique under simulative physiological conditions. Fluorescence analysis demonstrated that the quenching mechanism of HSA by Pd(II) complexes was static fluorescence quenching and hydrogen bonds and van der Waals interactions were the main intermolecular force based on thermodynamic data. The HSA–Pd(II) complex interaction had a high affinity of 10⁵ M^?1, and the number of binding sites n is almost 1. The results of synchronous fluorescence, three-dimensional fluorescence spectra, UV–Vis absorption and CD spectroscopy indicated that these two complexes may induce the microenvironment around the tryptophan residues and the conformation of human serum albumin. The binding distance (r) in the interaction between Pd(II) complex and HSA was estimated by the efficiency of fluorescence resonance energy transfer (FRET). Furthermore, results from multiple spectroscopic studies are consistent and indicate that the antitumor Pd(II) complexes can efficiently bind with human serum albumin molecules, providing a reasonable model that can help in understanding the design, transportation and toxic effects of anticancer agents.     

Spectroscopic studies on binding of Puerarin to human serum albumin

The interaction between Puerarin with human serum albumin has been studied for the first time by spectroscopic methods including fluorescence quenching technology, circular dichroism (CD) spectroscopy and Fourier transform infrared (FT-IR) spectroscopy under simulative physiological conditions. The results of fluorescence titration revealed that Puerarin can strongly quench the intrinsic fluorescence of HSA by static quenching and there is a single class of binding site on HSA. In addition, the studies of CD spectroscopy and FT-IR spectroscopy showed that the binding of Puerarin to HSA changed slightly molecular conformation of HSA. Furthermore, the thermodynamic functions ΔH⁰ and ΔS⁰ for the reaction were calculated to be −9.067 kJ mol⁻¹ and 54.315 J mol⁻¹ K⁻¹ according to van’t Hoff equation. These data suggested that both hydrogen bond and hydrophobic interaction play a major role in the binding of Puerarin to HSA, which is in good agreement with the result of molecular modeling study.     

Synthesis,structural determination and HSA interaction studies of a new water-soluble Cu(II) complex derived from 1,10-phenanthroline and ranitidine drug

A new water-soluble Cu(II) complex containing ranitidine drug and 1,10-phenanthroline was synthesized and characterized by elemental analysis, molar conductivity, spectroscopic and computational methods. In vitro human serum albumin (HSA)-interaction studies of Cu(II) complex were performed by employing fluorescence spectroscopy in combination with UV–vis absorption and circular dichroism (CD) spectroscopies. The results of fluorescence titration showed that Cu(II) complex strongly quenched the intrinsic fluorescence of HSA through a static quenching mechanism with an intrinsic binding constant (6.05 × 10⁴ M^?1) at 286 K. The thermodynamic parameters ΔG, ΔH, and ΔS at different temperatures were calculated and suggested that the hydrophobic and hydrogen bonding interactions play major roles in Cu(II) complex-HSA association. The displacement experiments using warfarin and ibuprofen as site I and II probes proved that the Cu(II) complex could bind to site I (subdomain IIA) of HSA. Finally, CD spectra indicated that the interaction of the Cu(II) complex with HSA leads to an increase in the α-helical content. The main result of this study was the finding that the binding affinity of the Cu(II) complex to HSA is three orders of magnitude stronger than that of ranitidine drug.     

白杨素与不同构型人血清白蛋白的作用机制

采用多种光谱学手段研究了白杨素(CHR)和不同构型人血清白蛋白(HSA)相互作用的分子机制.研究表明,白杨素能使蛋白质荧光发射峰发生静态淬灭,同时,白杨素的紫外吸收谱带也发生了明显的位移,说明与蛋白质的结合可使白杨素分子中的酚羟基发生解离.蛋白质还可以引起白杨素荧光发射峰强度的明显增强.利用荧光淬灭和荧光增强两种模式计算得到的白杨素和人血清白蛋白在生理条件下(pH 7.4)的结合常数(KA)分别为(9.97±0.24)×104和(9.75±0.11)×104L mol-1,其结合比例为1:1.随着pH值的降低,蛋白质与白杨素的结合常数逐渐减小,这与蛋白质的构型变化有关.根据不同异构体血清蛋白质的结构特征,判定白杨素在蛋白质分子上的结合位置位于IIA亚域的Site I活性位点.结合分子模拟,讨论了白杨素与蛋白质分子的结合机制.     

Investigating the interaction of juglone (5-hydroxy-1, 4-naphthoquinone) with serum albumins using spectroscopic and in silico methods

The interaction between juglone at the concentration range of 10–110 µM and bovine serum albumin (BSA) or human serum albumin (HSA) at the constant concentration of 11 µM was investigated by fluorescence and UV absorption spectroscopy under physiological-like condition. Performing the experiments at different temperatures showed that the fluorescence intensity of BSA/HSA was decreased in the presence of juglone by a static quenching mechanism due to the formation of the juglone–protein complex. The binding constant for the interaction was in the order of 10³ M^?1, and the number of binding sites for juglone on serum albumins was determined to be equal to one. The thermodynamic parameters including enthalpy (ΔH), entropy (ΔS) and Gibb’s free energy (ΔG) changes were obtained by using the van’t Hoff equation. These results indicated that van der Waals force and hydrogen bonding were the main intermolecular forces stabilizing the complex in a spontaneous association reaction. Moreover, the interaction of BSA/HSA with juglone was verified by UV absorption spectra and molecular docking. The results of synchronous fluorescence, UV–visible and CD spectra demonstrated that the binding of juglone with BSA/HSA induces minimum conformational changes in the structure of albumins. The increased binding affinity of juglone to albumin observed in the presence of site markers (digoxin and ibuprofen) excludes IIA and IIIA sites as the binding site of juglone. This is partially in agreement with the results of molecular docking studies which suggests sub-domain IA of albumin as the binding site.     

Human serum albumin interaction studies of a new copper(II) complex containing ceftobiprole drug using molecular modeling and multispectroscopic methods

A copper(II) complex containing the ceftobiprole drug and 1,10-phenanthroline (phen) has been synthesized and characterized by UV–vis, FT-IR and mass spectra, and elemental analysis. The binding interaction between [Cu(cef)(phen)Cl₂] complex and human serum albumin (HSA) was investigated using absorption, fluorescence emission and circular dichroism spectroscopies, and molecular docking. Thermodynamic parameters (ΔH < 0 and ΔS < 0) indicated that the hydrogen bond and van der Waals interactions played main roles in the binding of complex [Cu(cef)(phen)Cl₂] to HSA. The results of CD and UV–vis spectroscopy showed that the binding of [Cu(cef)(phen)Cl₂] to HSA induces some conformational changes in HSA. Displacement experiments predicted that the binding of [Cu(cef)(phen)Cl₂] complex to HSA is located within domain III, Sudlow’s site 2, and these observations were substantiated by molecular docking studies.     

Interaction Between Toddalolatone and Human Serum Albumin

A combination of fluorescence, UV–Vis absorption, circular dichroism (CD), Fourier transform infrared (FT-IR) spectroscopic and molecular modeling approaches was employed to investigate the interaction between toddalolactone (TDT) and human serum albumin (HSA) at physiological buffer conditions (pH 7.4). Fluorescence titration suggests that the mechanism of the fluorescence quenching of HSA is static, resulting from the formation of a TDT–HSA complex. Binding parameters calculated from the modified Stern–Volmer equation show that TDT binds to HSA with high affinity. Negative enthalpy change and positive entropy change values suggest that the binding process is primarily driven by hydrophobic interactions and hydrogen bonds. The binding of TDT to HSA results in an increase in the surface hydrophobicity of HSA. The binding distance between the Trp-214 residue (donor) and TDT (acceptor) was determined to be 4.18 nm based on the Förster theory of non-radioactive energy transfer. Displacement studies of site markers reveal that the binding site of TDT to HSA is located in the subdomain IIA (Sudlow’s site I). Furthermore, the molecular docking results corroborate and illustrate the specific binding mode and binding site. Analysis of UV–Vis absorption, CD and FT-IR spectra demonstrated that TDT induced a small alteration of the protein’s conformation.     

Molecular modeling and spectroscopic studies on binding of 2,6-bis[4-(4-amino-2-trifluoromethylphenoxy)benzoyl] pyridine to human serum albumin

BAFP (2,6-bis[4-(4-amino-2-trifluoromethylphenoxy)benzoyl] pyridine), a synthesized polyimide compound, was exploited for the first time to analyze its interaction with human serum albumin (HSA) by molecular modeling, fluorescence and Fourier transform infrared attenuated total reflection spectroscopy (FTIR ATR) with drug concentrations of 3.3 × 10⁻⁶ to 3.0 × 10⁻⁵ mol L⁻¹. Molecular docking was performed to reveal the possible binding mode. The results suggested that BAFP can strongly bind to human serum albumin (HSA) and the primary binding site of BAFP is located in site II of HSA, which is supported by the results from the competitive experiment. The binding constants for the interaction of BAFP with HSA have been evaluated from relevant fluorescence data at different temperatures (296, 303, 310 and 308 K). The alterations of the protein secondary structure in the presence of BAFP in aqueous solution were quantitatively calculated by the evidences from FTIR ATR spectroscopes. The binding process was exothermic and spontaneous, as indicated by the thermodynamic analyses, and the major part of the binding energy is hydrophobic interaction, which is also in good agreement with the results of molecule modeling study. The enthalpy change ΔH⁰, the free energy change ΔG⁰ and the entropy change ΔS⁰ of 296 K were calculated to be −7.75, −27.68 kJ mol⁻¹ and 67.33 J mol⁻¹ K⁻¹, respectively.